BIOMARKERS FOR USE IN THE DIAGNOSIS AND TREATMENT OF COLORECTAL CANCER

• US 20080020940A1
• Filed: 07/24/2007
• Published: 01/24/2008
• Est. Priority Date: 07/24/2006
• Status: Abandoned Application

• Current Assignee: Miraculins, Inc. (Britannia Life Sciences, Inc.)
• Original Assignee: Miraculins, Inc. (Britannia Life Sciences, Inc.)
• Inventors: Stedronsky, Katrin, Barker, Douglas, Zhang, Yilan
• Application Number:
  US11/782,368
• Publication Number:
  US 20080020940A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: A61K 38/4833 Thrombin (3.4.21.5)
• CPC Class Codes: G01N 2030/027 Liquid chromatography
• CPC Class Codes: G01N 27/447 using electrophoresis
• CPC Class Codes: G01N 30/7233 interfaced to liquid or supercritical fluid chromatograph interfaces in general for introducing or extracting samples to be analysed with specially adapted mass spectrometer, see H01J49/04
• CPC Class Codes: G01N 33/57419 of colon
• CPC Class Codes: G01N 33/6848 Methods of protein analysis involving mass spectrometry

Abstract

The present invention relates to the field of the diagnosis of large intestine diseases. More particularly, embodiments of the invention provide a method for differential diagnosis of colorectal cancer from a non-malignant disease of the large intestine, and from a healthy large intestine.

Claims

1. A method for diagnosing colorectal cancer in a subject comprising:

(a) obtaining a biological sample from the subject;

(b) detecting a quantity, presence, or absence of one or more of biomarkers M1, M2, M3, M4, M5, or M6 in said sample;

(c) classifying said subject as having or not having colorectal cancer, based on said quantity, presence, or absence of said biomarkers.

2. The method according to claim 1, wherein the step of classifying said subject comprises comparing the quantity, presence or absence of at least one of said biomarkers with a reference biomarker panel indicative of a colorectal cancer.

5. The method according to claim 1, wherein one or more said biomarkers are used to classify said subject by:

(a) contacting the biological sample with a biologically active surface,

(b) allowing the biomarkers within the biological sample to bind to the biologically active surface;

(c) detecting a bound biomarker using a detection method, wherein the detection method generates mass profiles of said biological sample;

(d) transforming information obtained in (c) into a computer readable form; and

(e) comparing the information in (d) with a database containing mass profiles from subjects whose classification is known;

wherein said comparison allows for the differential diagnosis and classification of a subject.

6. The method according to claim 5, wherein the database is generated by

(a) obtaining reference biological samples from subjects having a known classification;

(b) contacting the reference biological samples in (a) with a biologically active surface,

(c) allowing biomarkers within the reference biological samples to bind to the biologically active surface,

(d) detecting bound biomarkers using a detection method, wherein the detection method generates mass profiles of said reference biological samples,

(e) transforming the mass profiles into a computer-readable form, and

(f) applying a mathematical algorithm to classify the mass profiles in (d) into desired classification groups.

7. The method according to claim 1, wherein the quantity, presence, or absence of one or more of the biomarkers is detected in the biological sample obtained from the subject by mass spectrometry.

8. The method according to claim 7, wherein the method of mass spectrometry is selected from the group consisting of matrix-assisted laser desorption ionization/time of flight (MALDI-TOF), surface enhanced laser desorption ionisation/time of flight (SELDI-TOF), liquid chromatography, MS-MS, or ESI-MS.

9. The method according to claim 1, wherein the quantity, presence, or absence of the biomarker is detected or quantified in the biological sample obtained from the subject utilizing an antibody to said biomarker.

10. The method according to claim 1, wherein the quantity, presence, or absence of the biomarker is detected or quantified in the biological sample obtained from the subject by an ELISA assay.

11. The method according to claim 1, wherein the subject is a mammal.

12. The method according to claim 11, wherein the mammal is a human.

13. The method according to claim 1, wherein the biological sample is selected from the group consisting of:

blood, serum, plasma, urine, semen, seminal fluid, seminal plasma, prostatic fluid, pre-ejaculatory fluid (Cowper'"'"'s fluid), excreta, tears, saliva, sweat, biopsy, ascites, cerebrospinal fluid, lymph, and tissue extract sample or biopsy

14. The method according to claim 5, wherein the biologically active surface comprises an adsorbent consisting of cationic, quaternary ammonium groups.

17. The method according to claim 1, wherein the biomarkers are M1 and M4.

18. The method according to claim 1, wherein the biomarkers are M1 and M5.

19. The method according to claim 1, wherein the biomarkers are M1 and M6.

20. The method according to claim 1, wherein the biomarkers are M3 and M4.

21. The method according to claim 1, wherein the biomarkers are M3 and M5.

22. The method according to claim 1, wherein the biomarkers are M3 and M6.

23. The method according to claim 1, wherein the biomarkers are M2 and M4.

24. The method according to claim 1, wherein the biomarkers are M2 and M5.

25. The method according to claim 1, wherein the biomarkers are M2 and M6.

26. The method according to claim 1, wherein the biomarkers are M1, M2, M3, M4, M5 and M6.

3. A method for differential diagnosis of colorectal cancer and non-malignant disease of the large intestine in a subject, comprising:

(a) obtaining a biological sample from the subject;

(b) detecting a quantity, presence, or absence of one or more of biomarkers M1, M2, M3, M4, M5, and M6 in said sample;

(c) classifying said subject as having colorectal cancer, as having non-malignant disease of the large intestine, or as healthy, based on the quantity, presence, or absence of one or more said biomarkers in said biological sample.

4. The method according to claim 3, wherein classifying said subject comprises comparing the quantity, presence, or absence of at least one of said biomarkers with a reference biomarker panel indicative of colorectal cancer and a reference biomarker panel indicative of a non-malignant disease of the large intestine.

15. A database containing a plurality of database entries useful in diagnosing subjects as having or not having colorectal cancer, comprising:

(a) a categorization of each database entry as either characteristic of having or not having colorectal cancer;

(b) a characterisation of each database entry as either having, not having, or having in a certain quantity, a biomarker selected from the group consisting of biomarker M1, M2, M3, M4, M5, and M6.

16. A database generated by:

(a) obtaining reference biological samples from subjects known to have, and patients known not to have, colorectal cancer;

(b) contacting the reference biological samples in (a) with a biologically active surface;

(c) allowing biomarkers within the reference biological samples to bind to the biologically active surface;

(d) detecting bound biomarkers using a detection method wherein the detection method generates mass profiles of said reference biological samples;

(e) transforming the mass profiles into a computer readable form; and

(f) applying a mathematical algorithm to classify the mass profiles in (d) as specific for healthy subjects or subjects having colorectal cancer.

27. A method for determining the stage of colorectal cancer in a subject comprising:

(a) obtaining a biological sample from the subject

(b) detecting the quantity of one or more of biomarkers M1, M2, M3, M4, M5 or M6 in said sample

(c) classifying said subject as having stage 0 or stage I or stage IIA or stage IIB or stage IIIA or stage IIIB or stage IIIC or stage IV colorectal cancer

28. A method according to claim 27, wherein the step of determining the stage of colorectal cancer in a subject comprises comparing the quantity of at least one of said biomarkers with a referenced panel indicative of stage 0 or stage I or stage IIA or stage IIB or stage IIIA or stage IIIB or stage IIIC or stage IV colorectal cancer.